Poly Medicure Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 1.0 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure's board, meeting on August 8, 2025, approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations rose to ₹38,404.67 lakhs from ₹36,742.47 lakhs a year ago, while profit after tax grew about 21.6% to ₹8,792.89 lakhs. On a consolidated basis, revenue from operations was ₹40,321.07 lakhs and PAT was ₹9,308.29 lakhs, up roughly 25.7% year-on-year. Statutory auditors Doogar & Associates issued an unmodified review report. The board also re-appointed two independent directors, appointed Mr. Pankaj Kumar Gupta as Executive Director, granted 3,400 stock options under the ESOP 2020 scheme, and re-appointed M/s Jai Prakash & Company as cost auditors for FY25-26.
Solid double-digit profit growth, especially on a consolidated basis, signals healthy operating momentum for shareholders. The director changes and ESOP grant are routine governance items and unlikely to materially move the stock; investors should watch margin trends and QIP fund utilisation for the next quarters.